Payment overview · 2025
General Payments
$1,088.04
37 reported records · 16 companies
Healthcare provider profile · identity verified
Mark Thomas Gurley, M.D.
Allopathic & Osteopathic Physicians|Otolaryngology · KNOXVILLE, TN · NPI 1285751818
Verified facts
What the public records show
CMS Open Payments records show Mark Thomas Gurley, M.D. received $1,088.04 in general payments during 2025 across 37 reported records.
GENZYME CORPORATION accounted for 33.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ryaltris.
Hikma Pharmaceuticals USA reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ryaltris as an associated drug or biological on 1245 records involving 1030 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Ryaltris by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $362.44 | 33.3% | 11 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $143.23 | 13.2% | 5 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$121.35 | 11.2% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $95.13 | 8.7% | 4 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $56.99 | 5.2% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $44.42 | 4.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $37.68 | 3.5% | 2 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $34.66 | 3.2% | 2 | 2025 |
| Integra LifeSciences Corporation | Unresolved — no canonical attribution shown | $30.81 | 2.8% | 1 | 2025 |
| Neurent Medical Limited | Unresolved — no canonical attribution shown | $28.73 | 2.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $27.61 | 2.5% | 1 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $25.44 | 2.3% | 1 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $24.65 | 2.3% | 1 | 2025 |
| Hikma Pharmaceuticals USA | Unresolved — no canonical attribution shown | $18.73 | 1.7% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $18.52 | 1.7% | 1 | 2025 |
| Acera Surgical, Inc. | Unresolved — no canonical attribution shown | $17.65 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,011.74 | 35 |
| Education | $76.30 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc., SANOFI-AVENTIS U.S. LLC | $562.66 | 17 | 2025 |
Source payment records
|
|||||
| PROPEL Normalized: propel |
Device | Medtronic, Inc. | $107.24 | 1 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $95.13 | 4 | 2025 |
Source payment records
|
|||||
| Rhapsido Normalized: rhapsido |
Drug | Novartis Pharmaceuticals Corporation | $44.42 | 2 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $37.68 | 2 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $34.66 | 2 | 2025 |
Source payment records
|
|||||
| ACCLARENT AERA Normalized: acclarent aera |
Device | Integra LifeSciences Corporation | $30.81 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRA AIR Normalized: inspira air |
Device | Integra LifeSciences Corporation | $30.81 | 1 | 2025 |
Source payment records
|
|||||
| RELIEVA SPINPLUS NAV Normalized: relieva spinplus nav |
Device | Integra LifeSciences Corporation | $30.81 | 1 | 2025 |
Source payment records
|
|||||
| TruDi Probe Normalized: trudi probe |
Device | Integra LifeSciences Corporation | $30.81 | 1 | 2025 |
Source payment records
|
|||||
| NEUROMARK Radiofrequency Console Normalized: neuromark radiofrequency console |
Device | Neurent Medical Limited | $28.73 | 1 | 2025 |
Source payment records
|
|||||
| NEUROMARK System Normalized: neuromark system |
Device | Neurent Medical Limited | $28.73 | 1 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $27.61 | 1 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $25.44 | 1 | 2025 |
Source payment records
|
|||||
| PERCLOT Normalized: perclot |
Device | Baxter Healthcare | $24.65 | 1 | 2025 |
Source payment records
|
|||||
| Ryaltris Normalized: ryaltris |
Drug | Hikma Pharmaceuticals USA | $18.73 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $18.52 | 1 | 2025 |
Source payment records
|
|||||
| Restrata Wound Matrix Normalized: restrata wound matrix |
Device | Acera Surgical, Inc. | $17.65 | 1 | 2025 |
Source payment records
|
|||||
| SLIDE-ON ENDOSHEATH Normalized: slide on endosheath |
Device | Medtronic, Inc. | $14.11 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ryaltris ryaltris |
2025 | Ryaltris | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Hikma Pharmaceuticals USA Exact reporting entity; no affiliate inference |
2025 | Ryaltris open payments reported associated product |
CMS Open Payments — General Payments 1245 supporting records · 1030 recipient NPIs · example record 1248215996 |
Ryaltris · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Fluticasone Propionate | Fluticasone Propionate | 238 | 111 |
| Ipratropium Bromide | Ipratropium Bromide | 204 | 89 |
| Montelukast Sodium | Montelukast Sodium | 129 | 29 |
| Fluocinolone Acetonide Oil | Fluocinolone Acetonide Oil | 94 | 57 |
| Famotidine | Famotidine | 92 | 29 |
| Mupirocin | Mupirocin | 72 | 55 |
| Azelastine Hcl | Azelastine Hcl | 54 | 25 |
| Prednisone | Prednisone | 50 | 34 |
| Omeprazole | Omeprazole | 45 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 40 | 39 |
| Dupixent Pen | Dupilumab | 34 | suppressed |
| Lorazepam | Lorazepam | 28 | 28 |
| Ofloxacin | Ofloxacin | 28 | 26 |
| Ryaltris | Olopatadine Hcl/Mometasone | 26 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Cefdinir | Cefdinir | 22 | 22 |
| Clindamycin Hcl | Clindamycin Hcl | 22 | 16 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 22 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 22 | 21 |
| Olopatadine Hcl | Olopatadine Hcl | 19 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Epinephrine | Epinephrine | 16 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 15 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,088.04 · 37 records | GENZYME CORPORATION | ACCLARENT AERA, DUPIXENT, INSPIRA AIR, INSPIRE, KEYTRUDA, NEFFY, NEUROMARK Radiofrequency Console, NEUROMARK System, NUCALA, PERCLOT, PROPEL, RELIEVA SPINPLUS NAV, Restrata Wound Matrix, Rhapsido, Ryaltris, SLIDE-ON ENDOSHEATH, TEZSPIRE, TruDi Probe, Xhance | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ryaltris play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Hikma Pharmaceuticals USA?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error